Experimental Treatments for Terminal Conditions and Life-threatening Rare Diseases
Do you support it?
Want to know if it passes?
We'll email you when SB 1552 moves — a committee vote, a floor vote, or a signature. Nothing else.
Free forever · unsubscribe in one click.
Your answer was recorded either way.
Which district are you in?
Your ZIP is all we need to match you to your own representatives — so we can tell you how they voted on SB 1552.
You're tracking SB 1552
We'll email you the moment it moves.
SB 1552 — Experimental Treatments for Terminal Conditions and Life-threatening Rare Diseases
Last action — Died in Health Policy
No card. One bill, free forever — alerts when it moves.
-
1Introduced
-
2In Committee
-
3Passed Senate
-
4Passed House
-
5To Executive
-
6Enacted
This bill has been introduced in the Senate. Introduced January 09, 2026. It must pass committee before a floor vote.
Next likely step: a committee referral and hearing.
Prognosis
Where this bill stands today.
Odds of enactment
LowHow often bills like it became law.
Not enough signal yet to read this bill's trajectory — we surface a likelihood only once there's real movement (stage, sponsorship, committee, or votes) to point to.
Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.
Summary
Experimental Treatments for Terminal Conditions and Life-threatening Rare Diseases; Citing this act as the “Promising Pathways Act"; authorizing licensed physicians to prescribe and eligible facilities to administer experimental treatments, if certain requirements are met; requiring the Department of Health to establish and maintain a patient registry for specified purposes; encouraging health insurers and health maintenance organizations to provide specified insurance coverage for experimental treatments; authorizing licensed physicians and eligible facilities to receive reimbursement for the prescription or administration of experimental treatments if certain requirements are met; requiring manufacturers of experimental treatments to provide for a specified temporary price concession set by the department, etc.
Bill Text
- Introduced S 1552 Filed Current pdf
AI-generated reading aid from the bill's amendatory text — verify against the official bill.
The bill establishes a regulated pathway for providing experimental treatments to patients with terminal conditions and life-threatening rare diseases in Florida.
-
Section 499.0295, F.S.
Experimental treatments for terminal conditions and life-threatening rare diseases.—
This section is newly established to define the context and regulations for experimental treatments.
-
Section 499.0295, F.S.
(1) The Legislature finds that residents of this state with terminal conditions and life-threatening rare diseases may benefit from access to experimental treatments that have demonstrated initial human safety but are not yet approved by the United States Food and Drug Administration.
States the legislative intent to allow access to potentially beneficial experimental treatments.
-
Section 499.0295, F.S.
(2) It is the intent of the Legislature to: (a) Create a safe, regulated, and transparent pathway to experimental treatments through licensed state institutions with board oversight. (b) Condition payment on evidence development. (c) Encourage coverage parity by state-regulated health plans. (d) Align temporary pricing during the conditional period with the maturity of clinical evidence.
Defines the legislative intents for the regulation and facilitation of access to experimental treatments.
-
Section 499.0295, F.S.
(3) As used in this section, the term: (e) 'Eligible patient' means a person who: 1.a. Has a terminal condition that is attested to by the treating physician and confirmed by a board-certified physician in an appropriate specialty for that condition; or b. Has a life-threatening rare disease that is attested to by the treating physician and confirmed by a board-certified physician in an appropriate specialty. 2. Has considered and exhausted all other treatment options currently approved by the United States Food and Drug Administration.
Defines criteria for patients eligible to receive experimental treatments.
-
Section 499.0295, F.S.
(4) A physician licensed under chapter 458 or chapter 459 may prescribe to an eligible patient an experimental treatment pursuant to this section.
Authorizes licensed physicians to prescribe experimental treatments to eligible patients.
-
Section 499.0295, F.S.
(5) A platform or master protocol must be approved by an IRB under which treating physicians and eligible facilities may adapt dosing, sequencing, or combinations of authorized experimental treatments.
Establishes requirements for an Institutional Review Board (IRB) approval for administering experimental treatments.
-
Section 499.0295, F.S.
(6)(a) The department shall establish and maintain a patient registry for the collection and analysis of experimental treatment outcomes under this section.
Mandates the establishment of a registry to track the outcomes of patients receiving experimental treatments.
-
Section 499.0295, F.S.
(8) The Department of Health shall take appropriate steps to ensure patient safety and efficacy of treatment in compliance with all applicable laws.
Establishes a mandate for the Department of Health to oversee the safety and efficacy of treatments.
Action History
-
Died in Health Policy
-
Introduced
-
Referred to Health Policy; Appropriations Committee on Health and Human Services; Appropriations
-
Filed
Sponsors
- Danny Burgess · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 163 not signed on
Sponsors (1)
- Burgess, Danny Republican
Co-sponsors (0)
None.
Not signed on (163)
163 members have not signed on to this bill.
Show all 163 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does SB 1552 do?
- Experimental Treatments for Terminal Conditions and Life-threatening Rare Diseases; Citing this act as the “Promising Pathways Act"; authorizing licensed physicians to prescribe and eligible facilities to administer experimental treatments, if certain requirements are met; requiring the Department of Health to establish and maintain a patient registry for specified purposes; encouraging health insurers and health maintenance organizations to provide specified insurance coverage for experimental treatments; authorizing licensed physicians and eligible facilities to receive reimbursement for the prescription or administration of experimental treatments if certain requirements are met; requiring manufacturers of experimental treatments to provide for a specified temporary price concession set by the department, etc.
- Who sponsors SB 1552?
- SB 1552 is sponsored by Burgess, Danny (Republican).
- What is the current status of SB 1552?
- This bill has been introduced in the Senate. Introduced January 09, 2026. It must pass committee before a floor vote.
- Where can I track SB 1552?
- Track SB 1552 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on SB 1552
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of SB 1552
Last checked for changes 2 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →